IBDEI0YL ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17188,0)
 ;;=287.8^^111^1076^19
 ;;^UTILITY(U,$J,358.3,17188,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17188,1,1,0)
 ;;=1^287.8
 ;;^UTILITY(U,$J,358.3,17188,1,8,0)
 ;;=8^Oth Spec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,17188,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,17189,0)
 ;;=287.9^^111^1076^27
 ;;^UTILITY(U,$J,358.3,17189,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17189,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,17189,1,8,0)
 ;;=8^Unspec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,17189,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,17190,0)
 ;;=238.72^^111^1076^14
 ;;^UTILITY(U,$J,358.3,17190,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17190,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,17190,1,8,0)
 ;;=8^Low Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,17190,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,17191,0)
 ;;=238.73^^111^1076^12
 ;;^UTILITY(U,$J,358.3,17191,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17191,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,17191,1,8,0)
 ;;=8^Hi Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,17191,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,17192,0)
 ;;=238.75^^111^1076^15
 ;;^UTILITY(U,$J,358.3,17192,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17192,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,17192,1,8,0)
 ;;=8^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,17192,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,17193,0)
 ;;=205.00^^111^1077^32
 ;;^UTILITY(U,$J,358.3,17193,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17193,1,1,0)
 ;;=1^205.00
 ;;^UTILITY(U,$J,358.3,17193,1,8,0)
 ;;=8^Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,17193,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,17194,0)
 ;;=205.01^^111^1077^31
 ;;^UTILITY(U,$J,358.3,17194,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17194,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,17194,1,8,0)
 ;;=8^Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,17194,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,17195,0)
 ;;=205.10^^111^1077^18
 ;;^UTILITY(U,$J,358.3,17195,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17195,1,1,0)
 ;;=1^205.10
 ;;^UTILITY(U,$J,358.3,17195,1,8,0)
 ;;=8^Chr Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,17195,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,17196,0)
 ;;=205.11^^111^1077^17
 ;;^UTILITY(U,$J,358.3,17196,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17196,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,17196,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,17196,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,17197,0)
 ;;=289.0^^111^1077^50
 ;;^UTILITY(U,$J,358.3,17197,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17197,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,17197,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,17197,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,17198,0)
 ;;=238.4^^111^1077^48
 ;;^UTILITY(U,$J,358.3,17198,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17198,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,17198,1,8,0)
 ;;=8^Polycythemia Rubra Vera
 ;;^UTILITY(U,$J,358.3,17198,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,17199,0)
 ;;=288.9^^111^1077^67
 ;;^UTILITY(U,$J,358.3,17199,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17199,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,17199,1,8,0)
 ;;=8^Unspecified Dis Of W B C
 ;;^UTILITY(U,$J,358.3,17199,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,17200,0)
 ;;=289.81^^111^1077^49
 ;;^UTILITY(U,$J,358.3,17200,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17200,1,1,0)
 ;;=1^289.81
 ;;^UTILITY(U,$J,358.3,17200,1,8,0)
 ;;=8^Primary Hypercoagulable State
 ;;^UTILITY(U,$J,358.3,17200,2)
 ;;=^329886
 ;;^UTILITY(U,$J,358.3,17201,0)
 ;;=238.75^^111^1077^29
